A r t i c l e s
We studied six erythrocyte traits: hemoglobin concentration (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell count (RBC), as defined in Supplementary Table 1 . When cohort results were combined, 831 SNP associations at 23 independent loci (r 2 < 0.3 between loci) across the six traits reached the genome-wide significance threshold of P < 5 × 10 −8 . The -log 10 (P value) genome-wide association plots for the meta-analysis of each of the six traits are shown in Figure 1 , and corresponding quantile-quantile plots are shown in Supplementary  Figure 1a . To assess population structure, we examined the per-cohort genomic control inflation factor, λ GC , demonstrating that these values
RESULTS

Meta-analysis of GWAS for erythrocyte traits
The total sample size for the individual cohort genome-wide association analysis and the CHARGE meta-analysis was 24 . We also included an Italian cohort study, the Invecchiare in Chianti Study (InCHIANTI; N = 1,021), in these analyses. Characteristics of the study participants, including age, sex and trait summaries, are presented in Table 1 . table 1 cHArGe cohort description   AGES  ARIC  CHS  FHS  RS  InCHIANTI   Number of individuals eligible for GWAS  3,219  8,127  3,275  3,381  5,523  1,206   Percent women  58  53  61  54  60  56 Mean age (years) 51 (6) 54 (6) 72 (5) 38 (9) 68 (8) 68 (16) Hb (g/dl) 13 Years of baseline examinations 1968-1991 1987-1989 1989-1990 1971-1975 1990-1993 1998 Years of DNA collection 2002-2006 1987-1998 1989-1990 1996-1999 1990-1993 1998-2001 Sample sizes and summary statistics of covariates and erythrocyte traits measured in each cohort in CHARGE. Erythrocyte traits are abbreviated as follows: Hb, hemoglobin concentration; Hct, hematocrit; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RBC, erythrocyte count. The sample sizes presented are the range of numbers of individuals with both genotype and erythrocyte measures, after the exclusion of individuals with values beyond 3 s.d. of the population mean for each erythrocyte trait. Values for age and each erythrocyte trait are presented as mean (s.d.). NA, data not available.
Figure 1
Overview of CHARGE meta-analysis results for six erythrocyte traits: hemoglobin concentration (Hb), hematocrit (Hct), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV) and erythrocyte count (RBC). -log 10 (P value) is plotted on the y axis against the genomic position of each SNP. Genomic loci with significant association (P < 5 × 10 −8 ) are plotted in red, and loci with suggestive evidence are in blue (P < 4 × 10 −7 ). 1  2  3  4  6  5  7  8  9  11  10  12  13  14  15 16 17 18 19 20 21 22   BYSL  KCNIP1   PRKCE   BCL11A   SPTA1   BCL11A  TRIM58   TFRC   TFRC  KIT   HFE  BYSL   CD164   IZKF1  EPO   EPO   RCL1  MARCH8  FNTB ITGF3   MAST1  CHAF1A  C17orf63   TMEM163   AMT   KIT   HFE   HFE   HFE  BYSL   HBS1L-MYB   HBS1L-MYB   HBS1L-MYB   HBS1L-MYB   RCL1  NDUFB9  ITGF3   CHST9   MAST1   HBS1L-MYB   PRKAG2   PRKAG2  EPO   HK1   HK1   SH2B3   SH2B3   TSHZ2   TSHZ2   TMPRSS6   TMPRSS6   TMPRSS6   TMPRSS6  ECGF1 were consistently below 1.08 (Supplementary Table 2 ). The genomic control inflation factor post meta-analysis, which was not corrected at the meta-analysis level, showed no systematic inflation (Hb λ GC = 1.066; Hct λ GC = 1.045; MCH λ GC = 1.014; MCHC λ GC = 0.995; MCV λ GC = 1.029; and RBC λ GC = 1.029; Supplementary Table 2 ). The meta-analysis results for all traits are summarized in Table 2 , which is organized by the 23 independent loci and includes gene annotation information for each locus. The table also lists for each trait the number of SNPs exceeding the significance threshold. Altogether, there were 45 trait-locus combinations with at least one genome-wide significant SNP. The complete set of SNP associations identified by the CHARGE meta-analysis is provided in Supplementary Table 3 .
Replication and further analysis focused on the 45 SNPs that gave the smallest P values for each of the 45 trait-locus findings in CHARGE.
Replication studies
We pursued replication of the 45 SNPs identified from the initial metaanalysis in the CHARGE datasets, with a meta-analysis of association data in 9,456 independent European-ancestry individuals from five population-based cohorts of the HaemGen Consortium (Supplementary Note). A combined meta-analysis of the HaemGen and CHARGE data showed lower P values for all but two SNPs selected for replication. For one of the two SNPs (rs1800562) that did not show an improvement in P value when associated with Hct, the association to the Hb trait was significant after Bonferroni correction, and for the second SNP (rs4466998), the association to MCV in the joint analysis of CHARGE and HaemGen data remained genome-wide significant (P = 4.91 × 10 −8 ). Significant independent replication for at least one trait was observed at 13 of 23 loci, using a Bonferroni-corrected significance threshold of P < 0.0011, or 0.05/45 , and the distribution of replication P values is shown in Supplementary Figure 1b . Taking the joint metaanalysis results in sum, these data provide supportive evidence that the 23 loci from the discovery meta-analysis are true positives. Table 3 provides the full replication results, including beta coefficients, standard errors and P values, for the primary CHARGE findings, the HaemGen replication and a combined meta-analysis of the two datasets. For each lead SNP in the 23 independent loci, percent variance explained for each of the lead SNPs in the corresponding trait is provided in Table 3 , averaging the percent variance explained for each SNP across the CHARGE cohorts. The combination of lead SNPs from each of the trait loci showed that average percent variance explained by the combination of lead SNPs, beyond the variance explained by age and gender, was 1.14% of Hb variation (7 SNPs); 1.16% of Hct variation (8 SNPs); 4.53% of MCH variation (9 SNPs); 0.63% of MCHC variation (2 SNPs); 5.98% of MCV variation (17 SNPs); and 0.85% of RBC variation (2 SNPs). 
A r t i c l e s
Annotation of associated loci
For 20 of the identified loci, top associated SNPs were identified within a window of ±60 kb of a RefSeq gene ( Table 2) . For three loci, chromosomes 4q12, 6q24.1 and 20q13.2, no genes were identified within this window, with the nearest genes being approximately 116 kb, 89 Mb and 50 Mb away, respectively. Of the 23 loci, previously reported mutations or genetic associations for erythrocyte traits, markers of iron status or fetal hemoglobin levels have been noted at six loci containing the genes HFE, TFR2, TMPRSS6, SPTA1, HBS1L and MYB (two closely adjacent genes), and BCL11A. Most of the remaining loci have not previously been reported to be associated with erythrocyte traits, though several genes are known to have important roles in erythrocyte biology or erythropoiesis. Genes identified near the associated loci, and their associated erythrocyte traits, are presented in Table 2 and Figure 2 . Gene annotations, including gene information, known genetic mutations causing hematologic and nonhematologic diseases, and previously defined roles in hematologic and cardiovascular systems, are listed in Supplementary  Table 4 . We confirmed the association of the known mutations in the HFE gene resulting in the C282Y (rs1800562) and H63D (rs1799945) substitutions, mutations that are already known to underlie hereditary hemochromatosis, with Hb, Hct, MCH and MCV.
Gene expression in blood and endothelial cell lines
RNA expression levels for genes within a 1-Mb interval of each of the 23 loci we identified are presented in Supplementary Figure 2 , for erythroblasts (EBs), human umbilical vein endothelial cells (HUVECs) and seven other blood cell lines. For the top associated locus, chromosome 6q23.3, four genes were identified (ALDH8A1, HBS1L, MYB, AHI1) within the 1-Mb interval. A heat map showing gene expression levels for each of these four genes is shown in Figure 3 , demonstrating approximately twofold expression of MYB in EBs as compared to other cell lines. Gene expression was detected for genes in multiple loci (Supplementary Fig. 2) . Because the identification of gene expression in biologically relevant tissues provides a rationale for prioritization of candidate genes for further genetic or functional investigations, we noted broad categories of expression patterns in EBs and HUVECs. The most highly expressed genes in EBs were on chromosomes 3q29 (TFRC), 6p22.2 (HIST1H4C, which is near HFE), 6p21.1 (CCND3), 10q21.3 (HK1), 16p13.3 (HBZ, HBA1), and 22q12.3 (TST, RAC2). The genes most highly expressed in HUVECs were on chromosomes 6p22.2 (HIST1H4C), 7q22.1 (SERPINE1) and 22q13.3 (MFNG).
Association with blood pressure
The results of association testing for the 45 lead SNPs within 23 loci, as identified from the CHARGE meta-analysis, are summarized in Supplementary Table 5a . We identified associations at a Bonferronicorrected significance threshold of P < 0.00135 (0.05/37, as 37 of the 45 SNPs are unique) on chromosomes 12q24.1 (SH2B3) and 7q36.1 (PRKAG2). The previously reported association of the chromosome 12q24.1 locus SH2B3 with systolic blood pressure (SBP) and diastolic blood pressure (DBP) was the most significant association (rs1106598, SBP P = 1.2 × 10 −6 , HTN P = 0.0035; rs1763023, DBP P = 4.2 × 10 −8 ).
In the reported blood pressure and HTN analysis, signals at this locus spanned 700 kb, from rs3184504 to rs11066188, and association signals in Hb and Hct spanned 987 kb, from rs3184504 in SH2B3 to rs11066301 in PTPN11, and contained multiple genes 15 . Inspection of RNA expression data (Supplementary Fig. 2) showed that among A r t i c l e s genes in this region, SH2B3 and ATXN2 are highly expressed in erythroblasts and endothelial cells. Nominal associations (P < 0.05) were identified in the chromosomes 6p22.2 (HFE), 6q24.1, 7q22.1 (TFR2) and 20q12.3 (Supplementary Table 5a) ; results of the evaluation of SNPs associated with blood pressure and hypertension are presented in Supplementary Table 5b .
DISCUSSION
In this meta-analysis of genome-wide association data from 24,167 individuals of European ancestry from six cohort studies in the CHARGE Consortium, we identified 23 loci associated with at least one of the six erythrocyte traits Hb, Hct, MCH, MCHC, MCV and RBC. We sought evidence for replication in an additional 9,456 individuals of European ancestry from cohorts of the HaemGen Consortium. In the joint meta-analysis, combining CHARGE and HaemGen datasets, all 23 loci had P values <5 × 10 −8 , meeting our genome-wide significance threshold and suggesting that they merit further study. Among the 23 loci, six were previously known quantitative trait loci (QTLs), and 17 are newly associated loci, some of which include candidate genes whose products are known to be involved with iron homeostasis, erythropoiesis, globin synthesis and erythrocyte membrane function. Finally, an investigation of possible links between these erythrocyte traits and blood pressure and hypertension confirmed overlap at the previously known SH2B3 locus and identified additional suggestive associations, although none of these met our genome-wide significance threshold. The six erythrocyte traits examined here include some that are highly correlated, and as expected, we observed a high degree of concordance in the results across the six traits. Notably, MCHC, a ratio of Hb and Hct, two directly measured traits, is uniquely associated with chromosome 1q23.1 (SPTA1), a gene with several rare mutations known to cause deformation of erythrocytes 16, 17 . Reviewing the overall association results, we observed there were generally three patterns of significant associations among the six traits (Fig. 2) . Results were generally similar for (i) Hb and Hct, which are mainly quantitative measures of hemoglobin in the blood; (ii) MCH and MCV, representing erythrocyte size and quantity of hemoglobin per erythrocyte; and (iii) MCHC, the ratio of Hb to Hct, which appears somewhat distinct from the other traits. Across the six traits studied, the strongest signal was found in the HBS1L-MYB locus on chromosome 6q23, which was observed for five of the six individual traits (Hct, MCH, MCHC, MCV and RBC) at the genome-wide significance level. This locus also provided a modest but nonsignificant result for the sixth trait, Hb (rs4895441, P = 4.8 × 10 -4 ). In addition, the Hb/Hct and MCH/MCV patterns overlapped for associations to the chromosome 6p22.2 (HFE), 22q12.3 (TMPRSS6) and 7q22.1 (TFR2-EPO) loci. The RBC results represent a subset of the overlap between the Hb/Hct and MCH/MCV patterns, with associations observed in the 7q22.1 (TFR2-EPO) and 6q23 (HBS1L-MYB) loci. Across the erythrocyte traits, overlap occurs where known patterns of traits characterize various clinically observed hematologic diseases, providing a possible context in which to interpret the overlap of associations.
We annotated and categorized the findings of our analyses by association with known genetic disorders, biologic function or altered function of the hematopoietic system, to assist with interpretation of the findings (Supplementary Table 4) . We here consider these multiple findings in light of their potential role in several processes critical to erythrocyte biology, including iron homeostasis, erythrocyte membrane function, erythropoiesis and globin synthesis.
We identified genome-wide significant association of SNPs within the HFE gene with Hb, Hct, MCH and MCV. The mutation in HFE encoding the C282Y substitution is the principal cause of hereditary hemochromatosis, a common autosomal recessive iron overload disease in individuals of northern European descent 18 . This mutation was associated with increased MCV and Hb concentrations in a study of individuals drawn from a screening study for hemochromatosis and iron overload 7 , and this variant was the lead association result for both Hb and Hct in our study. Individuals heterozygous for either allele do not manifest clinical iron overload but may have an increased iron uptake and resistance to anemia, and the C282Y-encoding mutation may increase the risk of coronary heart disease by increasing iron stores and lipid oxidation 19, 20 . The HFE gene induces expression of the iron regulatory hormone hepcidin. Hepcidin has recently emerged as the likely link between the inflammatory response and the handling of iron for erythropoiesis through its actions in both downregulating the absorption of iron in the intestine and inhibiting the release of iron from macrophages [21] [22] [23] [24] . SNPs within TMPRSS6 were associated with Hb, Hct, MCH and MCV. TMPRSS6 was identified by linkage and association studies in five families and two sporadically affected individuals with iron-refractory iron-deficiency anemia, a rare mendelian disease 25 . TMPRSS6 encodes a type II transmembrane serine protease produced by the liver that regulates the expression of hepcidin 25 . The transferrin receptor (encoded by TFRC, also called TFR1) and transferrin receptor 2 (TFR2) are highly homologous type II transmembrane proteins in the transferrin protein family. SNPs within TFRC were associated with MCH and MCV, and SNPs within TFR2 were associated with Hct and MCV. Reduced TFRC expression is associated with anemia 26 . Existing evidence indicates that TFR2 is also a modulator of hepcidin expression and that mutations in TFR2 cause hemochromatosis type 3 (ref. 27) .
Two loci, chromosome 2p16.1 (BCL11A) associated with MCV, and chromosome 6q23.3 (HBS1L-MYB) associated with all traits except for Hb, are related to variation in fetal hemoglobin and hemoglobinβ levels 28, 29 . BCL11A is an oncogene related to B-cell malignancies 30 and regulates fetal hemoglobin expression 31 . BCL11A is expressed in erythroid precursors, and we observed BCL11A expression in EBs (Supplementary Fig. 2) , making it a biologically plausible candidate gene for erythrocyte trait variation 32 . A healthy-population study showed that polymorphisms in HBS1L and MYB influences erythrocyte, platelet and monocyte counts 10 . Although the role of HBS1L is unknown, MYB has been associated with proliferation, survival and differentiation of hematopoietic progenitor cells 33, 34 . MYB is also associated with eosinophil counts in blood and atopic asthma 35 . There are strong associations between SNPs within this locus and multiple erythrocyte traits (lead SNP rs4895441, Hb P = 4.8 × 10 −4 ; Hct P = 9.7 × 10 −10 ; MCH P = 7.8 × 10 −32 ; MCHC P = 4.5 × 10 −9 ; MCV P = 1.0 × 10 −57 ; and RBC P = 2.2 × 10 −15 ). These strong genetic effects may explain why several earlier linkage analyses of erythrocyte traits have identified this chromosomal region 6, 11, 13 . SNPs within SH2B3 are associated with Hct and Hb. Notably, the SNPs within this gene are associated with blood pressure, myocardial infarction, type 1 diabetes and celiac disease 15, [35] [36] [37] [38] [39] . SH2B3 is expressed in hematopoietic precursor cells and increases hematopoietic progenitors of erythroid, megakaryocytic and myeloid lineages 35, 40 . SH2B3 is also expressed in vascular endothelium, where it promotes inflammation and may thereby contribute to vascular disease. Expression in different cell lineages and tissues may underlie the diverse pleiotropic effects of SH2B3 on hematopoietic traits, autoimmune diseases and vascular diseases. In the same locus, the PTPN11 gene product interacts with the transcription factor SHP2, which has an essential role in blood development that has been demonstrated in a murine Shp2 −/− model 41 , and PTPN11 mutations cause Noonan's and LEOPARD syndromes and juvenile myelomonocytic leukemia [42] [43] [44] . Lastly, we identified associations for Hct, MCV and RBC near the EPO gene. Erythropoietin, the EPO gene product, a glycoprotein hormone that controls erythropoiesis, is the first human recombinant hematopoietic protein approved for human use and is now used widely for the treatment of anemia. EPO variants have previously been described in association with diabetic retinal and renal vascular complications 45 but not with erythrocyte traits.
SNPs within the SPTA1 gene were associated with MCHC. SPTA1 encodes erythroid spectrin, a protein in the erythrocyte membrane that is essential in determining the shape and deformability of erythrocytes. Spectrin mutations have been previously associated with hemolytic anemia, elliptocytosis, spherocytosis and propoikilocytosis, but not with variations in MCHC outside of disease states 16, 17 .
The gene expression data may be viewed as additional annotation of the 23 loci we identified, confirming which genes are expressed in cell types of interest. These data may be used to generate further specific hypotheses that can then be tested at a functional and molecular level.
Multiple lines of evidence formed the basis of our rationale for studying the relationship of the SNPs identified through the study of erythrocyte traits to blood pressure and hypertension. Earlier studies have shown that Hb and Hct levels are associated with increased risks for hypertension and a variety of other vascular diseases and for mortality [1] [2] [3] [46] [47] [48] [49] . From a rheologic perspective, blood viscosity depends largely on Hb or Hct levels and is a determinant of blood pressure [50] [51] [52] [53] . There is an inverse relationship between viscosity and vascular blood flow 54 , and elevated Hct thereby hampers organ perfusion. Given these findings, we are intrigued by the overlap between the association results for Hb and Hct from our study and the recently reported associations for blood pressure and hypertension 15, 36 . We observed overlap of associations in the chromosome 12q24.12 region across a 98-kb linkage disequilibrium block containing SH2B3, ATXN2, BRAP, C12orf03, TRAFD1, ACAD10, TMEM116 and PTPN11. We also identified associations within the 7q36.1 region containing PRKAG2; this gene does not have specifically known hematologic or vascular roles, but mutations in the gene cause cardiomyopathy and disorders of the cardiac conduction system 55, 56 . Neither causality nor independence of these associations is necessarily supported by these findings. However, the associations suggest that common genetic bases may underlie some of the correlation seen between erythrocyte, blood pressure and hypertension traits. Further confirmation in large independent cohorts may provide stronger evidence for the strength and consistency of the associations with hypertension.
One limitation of the current analyses is that our study cohorts were limited to individuals of European ancestry. Several mutations affecting spectrin and globin have been identified in African American kindreds, and the prevalence of hemoglobinopathies of various types is generally higher among individuals of African ancestry, highlighting the need for further investigation of these findings in individuals of non-European ancestry 57 . As with any meta-analysis of genome-wide association results across different cohorts, population structure and other sources of heterogeneity may have caused false positives or false negatives. In the replication analysis, for those loci that did not meet a conservative replication test, power may have been limited, and many of these associations are likely to improve with additional study. Finally, the interpretation of multiple analyses of correlated traits requires caution, particularly in attributing causality or independence of effects. We take the findings from our analyses of the six erythrocyte traits to indicate a set of loci that are of interest with regard to erythrocyte production, homeostasis and function. Specific differences in association patterns between the individual traits examined may highlight different pathways, but further studies are needed to characterize these.
In summary, we have identified and validated common variants at several known and novel loci that influence the levels of six clinically relevant red blood cell measures in population-based cohorts. These QTLs have implications for understanding a variety of hematologic diseases as well as correlates of erythrocyte traits, such as blood pressure and hypertension. Further studies are needed to examine these associations in ethnically diverse populations and to characterize the functional impact of variants at the implicated candidate genes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Complete study acknowledgments are listed in the Supplementary Note. The authors thank the studies' participants and staff and the funding agencies for their support. to those previously reported meta-analysis within the CHARGE Consortium for systolic blood pressure (SBP), diastolic blood pressure (DBP) and hypertension 1, 2, 15 . The CHARGE cohorts that contributed samples to the blood pressure and hypertension analyses were AGES, ARIC, CHS, FHS and RS, with a total sample size of N = 29,136. SBP and DBP measured at the first visit attended were continuous traits, and hypertension was analyzed as a dichotomous trait 15 . We tested the association of the lead SNP per locus for each trait (45 SNPs) for association with SBP, DBP and hypertension 15 , using a Bonferroni-corrected threshold for the number of SNPs tested. We additionally reversed the analysis, examining the test statistics within each of the six erythrocyte traits for those SNPs reported to be associated with SBP, DBP or hypertension 15 .
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